Document is current
Any future updates will be listed below
-
Authors
Belyakova-Bodina, Alexandra https://orcid.org/0000-0002-2339-8483
Ratanov, Mikhail https://orcid.org/0000-0001-7898-4431
Schneider, Erich https://orcid.org/0000-0003-1039-9783
Seliverstov, Yury https://orcid.org/0000-0002-6400-6378
Nuzhnyi, Evgenii https://orcid.org/0000-0003-3179-7668
Klyushnikov, Sergey https://orcid.org/0000-0002-8752-7045
Broutian, Amayak https://orcid.org/0000-0002-6381-2925
- License Information
-
More Information
Article History
Received: 25 February 2021
Revised: 3 June 2021
Accepted: 4 June 2021
First Online: 12 June 2021
Declarations
:
: ABB and SK have received funding from Actelion Pharmaceuticals for the EyeSeeCam Sci system used in this study. ES is general manager and shareholder of EyeSeeTec GmbH. All the other authors declare no conflicts of interest.
: The research was approved by local ethical committee of Research Center of Neurology, Moscow, Russian Federation (protocol 9-2/18, 14 November 2018). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.
: All the patients gave informed consent to participate in the study.
: All the patients consented to their data publication.
